grant
Acute myeloid leukemia (AML) Research Project
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 5 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025ALL1ALL1 geneAML - Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia Protein 1Acute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAddressAntioncogene Protein p53B23 Nuclear Matrix ProteinBiologyCXXC7Cancer GenesCancer-Promoting GeneCancersCellular Tumor Antigen P53Chimera ProteinChimeric ProteinsClassificationClinicalCollectionCombined Modality TherapyCommunitiesComplexDNA AlterationDNA Sequence AlterationDNA mutationDNMT3aDataDevelopmentDiseaseDisorderDocumentationDrosophila Homolog of TrithoraxDrug CombinationsDrugsEngraftmentEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFLK2FLT3FLT3 geneFLT3 inhibitorFMS-like tyrosine kinase 3FailureFms-Related Tyrosine Kinase 3Fusion ProteinGeneticGenetic AlterationGenetic ChangeGenetic defectGenetic mutationHRXHeterograftHeterologous TransplantationHumanKMT2ALeukemic progenitor and stem cellLysine-Specific Methyltransferase 2AMLL fusion leukemiaMLL geneMLL leukemiaMLL1Malignant NeoplasmsMalignant TumorMedicationMeninMiceMice MammalsMixed Lineage Leukemia GeneMixed-Lineage LeukemiaMixed-Lineage Leukemia ProteinModelingModern ManMolecularMolecular Modeling Nucleic Acid BiochemistryMolecular Modeling Protein/Amino Acid BiochemistryMolecular ModelsMouse StrainsMultimodal TherapyMultimodal TreatmentMultiple lineage leukemia 1MurineMusMutateMutationMyeloid-Lymphoid Leukemia GeneMyeloid-Lymphoid Leukemia ProteinMyeloid/Lymphoid Leukemia GeneMyeloid/Lymphoid Or Mixed Lineage Leukemia ProteinMyeloid/Lymphoid or Mixed Lineage Leukemia GeneNGS MethodNGS systemNational Institutes of HealthNucleolar Phosphoprotein B23OncogenesOncoprotein p53P53PDX modelPathogenesisPatient derived xenograftPennsylvaniaPerformancePharmaceutical PreparationsPhasePhenotypePhosphoprotein P53Phosphoprotein pp53Pre-Clinical ModelPreclinical ModelsProtein TP53ProteinsProto Oncogene Proteins MLLR-Series Research ProjectsR01 MechanismR01 ProgramRNA SeqRNA sequencingRNAseqRelapseResearch GrantsResearch Project GrantsResearch ProjectsSTK-1 kinaseSTK1SamplingSequence AlterationStem Cell Tyrosine Kinase 1SubgroupSurvival RateSystematicsTP53TP53 geneTRP53TherapeuticTissue TransplantationTransforming GenesTransplant-Related DisorderTransplantationTumor Protein p53Tumor Protein p53 GeneUnited States National Institutes of HealthUniversitiesXenograftXenograft procedureXenotransplantationZinc Finger Protein HRXacute granulocytic leukemiaacute myeloid leukemiaadvanced diseaseadvanced illnesscohortcombination therapycombined modality treatmentcombined treatmentdevelop therapydevelopmentaldisease subgroupsdisease subtypedisorder subtypedrug detectiondrug developmentdrug testingdrug/agentepigeneticallyfetal liver kinase-2fetal liver kinase-3genome mutationgenomic alterationhDNA methyltransferase 3ain vivoinhibitorintervention developmentleukemialeukemia stem/initiating cellsleukemic progenitorleukemic stem cellmalignancymixed lineage leukemia 1molecular modelingmolecular targeted therapeuticsmolecular targeted therapiesmolecular targeted treatmentmulti-modal therapymulti-modal treatmentmutantneoplasm/cancernew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext gen sequencingnext generation sequencingnext generation therapeuticsnextgen sequencingnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetnucleolar protein B23nucleophosmidnucleophosminp53 Antigenp53 Genesp53 Tumor Suppressorpatient derived xenograft modelphase 2 trialphase II trialprotein B23protein p53responseresponse to therapyresponse to treatmenttargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapy developmenttherapy responsetranscriptome sequencingtranscriptomic sequencingtransplanttransplant diseasetreatment developmenttreatment responsetreatment responsivenessxeno-transplantxeno-transplantation
Description preview
Summary
Acute myeloid leukemia (AML) is one of the most intensely studied of human malignancies. In recent years
there have been major advances in defining the molecular pathogenesis of AML and introduction of new
therapies. But the three-year survival rate remains below 50% indicating failures to make therapeutic advances
for the disease. In…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click